Bing Cao1, Yan Chen2, Elisa Brietzke3, Danielle Cha4, Aisha Shaukat2, Zihang Pan2, Caroline Park2, Mehala Subramaniapillai2, Hannah Zuckerman2, Kiran Grant2, Rodrigo B Mansur2, Roger S McIntyre5. 1. Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing 100191, PR China; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada. 2. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada. 3. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada; Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil. 4. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada; Faculty of Medicine, School of Medicine, University of Queensland, Brisbane, QLD, Australia. 5. Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada; Department of Pharmacology, University of Toronto, Toronto, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada. Electronic address: roger.mcIntyre@uhn.ca.
Abstract
OBJECTIVES: To explore differences in adipokine levels (i.e., leptin and adiponectin levels) between adults with Major Depressive Disorder (MDD) and healthy controls (HC), and to discuss the possible role of adipokine regulation in the development and progression of MDD. METHODS: A systematic review and meta-analysis were conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A systematic search was conducted for all English and Chinese peer-reviewed articles from inception to November 2017. A random effects model was used to calculate the standardized mean difference (SMD) of leptin and/or adiponectin levels in subjects diagnosed with MDD versus HC within a 95% confidence interval (CI). RESULTS: Thirty-three studies were included in this meta-analysis. In total, 4,372 (52.3%) subjects with MDD and 3,984 (47.7%) HC were compared. We identified significant lower adiponectin levels in MDD compared to HC with a small effect size (ES) (SMD = -0.25; 95% CI: -0.48, -0.02; P < 0.001). However, no significant difference was observed in leptin levels between MDD subjects and HC (SMD = 0.13; 95% CI: -0.06, 0.31; P = 0.170). The heterogeneity in the results of our meta-analysis could not be completely explained by dividing subjects into subgroups. Results from subgroup analyses suggested that studies involving samples with BMI ≥ 25 had lower adiponectin levels in subjects with MDD compared to HC, and older age samples (i.e., age ≥ 40) with BMI ≥ 25 had both higher leptin levels and lower adiponectin levels in MDD subjects as compared to HC. LIMITATIONS: The heterogeneity of included studies, small sample sizes, and potential publication bias were significant limitations. CONCLUSIONS: The current systematic review and meta-analysis indicated that lower adiponectin levels may be associated with MDD. Moreover, the results suggest that males expressing lower adiponectin and leptin levels have an increased likelihood of developing MDD. Future studies should aim to investigate the manifestation of depressive phenotypes in older, obese populations with altered metabolic profiles resulting from adipokine dysregulation. The review has been registered with PROSPERO (registration number CRD42018082733).
OBJECTIVES: To explore differences in adipokine levels (i.e., leptin and adiponectin levels) between adults with Major Depressive Disorder (MDD) and healthy controls (HC), and to discuss the possible role of adipokine regulation in the development and progression of MDD. METHODS: A systematic review and meta-analysis were conducted based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. A systematic search was conducted for all English and Chinese peer-reviewed articles from inception to November 2017. A random effects model was used to calculate the standardized mean difference (SMD) of leptin and/or adiponectin levels in subjects diagnosed with MDD versus HC within a 95% confidence interval (CI). RESULTS: Thirty-three studies were included in this meta-analysis. In total, 4,372 (52.3%) subjects with MDD and 3,984 (47.7%) HC were compared. We identified significant lower adiponectin levels in MDD compared to HC with a small effect size (ES) (SMD = -0.25; 95% CI: -0.48, -0.02; P < 0.001). However, no significant difference was observed in leptin levels between MDD subjects and HC (SMD = 0.13; 95% CI: -0.06, 0.31; P = 0.170). The heterogeneity in the results of our meta-analysis could not be completely explained by dividing subjects into subgroups. Results from subgroup analyses suggested that studies involving samples with BMI ≥ 25 had lower adiponectin levels in subjects with MDD compared to HC, and older age samples (i.e., age ≥ 40) with BMI ≥ 25 had both higher leptin levels and lower adiponectin levels in MDD subjects as compared to HC. LIMITATIONS: The heterogeneity of included studies, small sample sizes, and potential publication bias were significant limitations. CONCLUSIONS: The current systematic review and meta-analysis indicated that lower adiponectin levels may be associated with MDD. Moreover, the results suggest that males expressing lower adiponectin and leptin levels have an increased likelihood of developing MDD. Future studies should aim to investigate the manifestation of depressive phenotypes in older, obese populations with altered metabolic profiles resulting from adipokine dysregulation. The review has been registered with PROSPERO (registration number CRD42018082733).
Authors: Lucas Renan Sena de Oliveira; Frederico Sander Mansur Machado; Isabella Rocha-Dias; Caíque Olegário Diniz E Magalhães; Ricardo Augusto Leoni De Sousa; Ricardo Cardoso Cassilhas Journal: Mol Biol Rep Date: 2022-01-29 Impact factor: 2.742
Authors: Faisal Akram; Claudia Gragnoli; Uttam K Raheja; Soren Snitker; Christopher A Lowry; Kelly A Stearns-Yoder; Andrew J Hoisington; Lisa A Brenner; Erika Saunders; John W Stiller; Kathleen A Ryan; Kelly J Rohan; Braxton D Mitchell; Teodor T Postolache Journal: J Psychiatr Res Date: 2020-01-02 Impact factor: 4.791
Authors: André F Carvalho; Marco Solmi; Marcos Sanches; Myrela O Machado; Brendon Stubbs; Olesya Ajnakina; Chelsea Sherman; Yue Ran Sun; Celina S Liu; Andre R Brunoni; Giorgio Pigato; Brisa S Fernandes; Beatrice Bortolato; Muhammad I Husain; Elena Dragioti; Joseph Firth; Theodore D Cosco; Michael Maes; Michael Berk; Krista L Lanctôt; Eduard Vieta; Diego A Pizzagalli; Lee Smith; Paolo Fusar-Poli; Paul A Kurdyak; Michele Fornaro; Jürgen Rehm; Nathan Herrmann Journal: Transl Psychiatry Date: 2020-05-18 Impact factor: 6.222